Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Down 34.1% in October

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 5,460,000 shares, a decrease of 34.1% from the September 30th total of 8,290,000 shares. Based on an average daily volume of 30,150,000 shares, the short-interest ratio is presently 0.2 days. Currently, 4.0% of the company’s shares are sold short.

Institutional Trading of Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent SEC filing. Institutional investors own 82.26% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TNXP shares. StockNews.com initiated coverage on Tonix Pharmaceuticals in a research note on Monday. They set a “sell” rating for the company. Alliance Global Partners upped their price target on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Stock Down 6.1 %

Shares of Tonix Pharmaceuticals stock traded down $0.01 on Tuesday, reaching $0.17. The stock had a trading volume of 11,781,505 shares, compared to its average volume of 10,047,852. Tonix Pharmaceuticals has a 1 year low of $0.12 and a 1 year high of $22.14. The company has a 50 day moving average price of $0.18 and a 200 day moving average price of $1.84. The company has a quick ratio of 0.72, a current ratio of 1.15 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $23.06 million, a P/E ratio of 0.00 and a beta of 2.08.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The company had revenue of $2.21 million for the quarter, compared to analyst estimates of $3.50 million. Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. As a group, equities research analysts forecast that Tonix Pharmaceuticals will post -18 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.